Context
Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on the development of products in the therapeutic areas of oncology and infectious diseases.
With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.
Basilea Pharmaceutica generates CHF 130m in annual revenues, driven by anti-infective drugs marketed in partnership with Pfizer, Astellas and others.
Its pipeline is successfully transitioning to oncology, with lead candidate Derazantinib showing positive Phase 2 results.
Proceeds from the Follow-on Offering will be used to finance the clinical development of Basilea Pharmaceutica’s clinical oncology drug candidates Derazantinib and Lisavanbulin, pre-clinical research and development activities, working capital and for other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.
About Basilea Pharmaceutica
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. It is committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. It has successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and has a number of preclinical assets in both cancer and infectious diseases in its portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Basilea Pharmaceutica on its CHF 46 million Follow-on Offering
Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner on Basilea Pharmaceutica’s Follow-on Offering.
Basilea Pharmaceutica raised CHF 46m, with large orders coming from Tier 1 long-only and biotech specialists. There was strong demand from the UK, Switzerland, Europe and the US.
• Book oversubscribed 2.6x with CHF 120m of demand.
• Pricing at CHF 45.75, 8.9% discount vs. closing price.
Prior to the offering, Bryan, Garnier & Co accompanied Basilea Pharmaceutica’s management on a virtual non-deal roadshow with 15+ investors across Europe, raising awareness of the company and research coverage.
This third capital raise for a biotech in 2021 and first on the Six Swiss Exchange in 2021 advised by Bryan, Garnier & Co marks another landmark transaction for the firm’s Healthcare and Equity Capital Markets franchises and the beginning of another strong year.
Share